Latest News

  • TapImmune Provides Update on PolyStart™ Vaccine ...

    Platform Technology is a novel platform for rapid development of Vaccines for Cancer and Multiple Emerging Viral Threats including Ebola, Enterovirus, and Smallpox.   SEATTLE, WASHINGTON,...

    Read more

  • Tapimmune, a Biotech Company Focused on Stimulatin...

    TapImmune, a biotech company focused on stimulating the body’s own immune system to fight cancer. Please listen to the interview with host Eric Michaels of eHealth Radio Network and TapImmune CEO...

    Read more

  • National Breast Cancer Awareness Month...

    A personal perspective from Dr Glynn Wilson, Chairman & CEO, TapImmune National Breast Cancer Awareness Month (NBCAM), is an annual international health campaign organized by major breast cancer...

    Read more

  • TapImmune CEO Provides Update on Corporate Activit...

    I am pleased to provide this update to existing shareholders and interested potential shareholders SEATTLE–(BUSINESS WIRE)– TapImmune is a clinical-stage immunotherapy company...

    Read more

  • SeeThruEquity Issues Company Update on TapImmune H...

    SeeThruEquity maintains price target of $6.97 per share and reiterates compelling valuation based on a number of factors including positive interim data on its Phase I clinical trial of folate...

    Read more

  • TapImmune Releases Positive Interim Data on Phase ...

    All Patients Developed Immune Responses as All Five Peptides Shown to be Immunogenic SEATTLE–(BUSINESS WIRE)–TapImmune Inc. (OTCQB:TPIV) is extremely pleased to report that analysis of...

    Read more

  • SeeThruEquity to Hold Fall Microcap Investor Confe...

    Conference Being Held at Convene Times Square in Midtown NEW YORK / ACCESSWIRE / September 8, 2014 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm...

    Read more

  • TapImmune Inc to Present at SeeThruEquity Microcap...

    Seattle, WA / ACCESSWIRE / September 4, 2014 / TapImmune, Inc. (TPIV), announces that company executives will attend and present at the SeeThruEquity Microcap Investor Conference to be held Thursday...

    Read more

  • TapImmune Inc to Present at 16th Annual Rodman �...

    Seattle WA / ACCESSWIRE / September 3, 2014 / TapImmune, Inc. (TPIV), a clinical-stage immunotherapy company specializing in the development of innovative peptide and gene-based immunotherapeutics...

    Read more

  • SeeThruEquity Issues Update Note on TapImmune High...

    New York, NY / ACCESSWIRE / August 19, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it...

    Read more

  • TapImmune, Inc. Announces $2 Million Registered Di...

    SEATTLE, Aug 11, 2014 (BUSINESS WIRE) — TapImmune, Inc. (the "Company"), (otcqb:TPIV), today announced that it has entered into a definitive agreement with an institutional investor for...

    Read more

  • TapImmune’s New Clinical Trial in Advanced S...

    SEATTLE–(BUSINESS WIRE)–TapImmune Inc. (OTCQB:TPIV) is pleased to announce that a new grant funded Phase I clinical study on the safety and Immunogenicity of folate receptor alpha peptide...

    Read more

  • TapImmune Prevails in Legal Dispute with Michael G...

    International Arbitration Tribunal Finds in Favor of TapImmune Inc., and Awards the Company $196,204 in Damages SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIV), announces successful...

    Read more

  • New Immunotherapy Technologies Provide Hope In Bre...

    Los Angeles / ACCESSWIRE / July 23, 2014 / Last month, TapImmune Inc. (TPIV) announced that Dr. Keith Knutson, PhD had been appointed to chair the company’s scientific advisory board. TapImmune, an...

    Read more

  • SeeThruEquity Issues Company Note on TapImmune Hig...

    New York, NY / ACCESSWIRE / July 1, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it...

    Read more

  • TapImmune Appoints Leading Immunotherapy Researche...

    SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIV) is pleased to announce that Dr. Keith Knutson, PhD (www.vgtifl.org/keith-knutson-phd) has been appointed to chair the company’s scientific...

    Read more

  • SeeThruEquity Initiates Research Coverage on TapIm...

    New York, NY / ACCESSWIRE / May 27, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it...

    Read more

  • TapImmune Inc. is Pleased to Announce the Filing o...

    New Technology Significantly Enhances the Presentation of Desired Peptides on the Surface of Cells for Targeting to the Immune System SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIVD), a...

    Read more

  • TapImmune Inc. is Pleased to Announce the Signing ...

    SEATTLE–(BUSINESS WIRE)– TapImmune Inc. (TPIVD), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and...

    Read more

  • TapImmune Inc. To Present at 2014 Annual Roth Capi...

    Seattle, WA / ACCESSWIRE / March 5, 2014 / TapImmune Inc. (TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of...

    Read more